top 646.ph

President-elect Donald Trump’s choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace — celebrity doctor Mehmet Oz — recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest. Oz’s holdings, some shared with family, included a stake in UnitedHealth Group worth as much as $600,000, as well as shares of pharmaceutical firms and tech companies with business in the health care sector, such as Amazon. Collectively, Oz’s investments total tens of millions of dollars, according to financial disclosures he filed during his failed 2022 run for a Pennsylvania U.S. Senate seat. Trump said Tuesday he would nominate Oz as administrator of the Centers for Medicare & Medicaid Services. The agency’s scope is huge: CMS oversees coverage for more than 160 million Americans, nearly half the population. accounts for approximately $1 trillion in annual spending, with over 67 million enrollees. UnitedHealth Group is one of the largest health care companies in the nation and arguably the most important business partner of CMS, through which it is the leading provider of commercial health plans available to Medicare beneficiaries. UnitedHealth also offers managed-care plans under Medicaid, the joint state-federal program for low-income people, and sells plans on government-run marketplaces set up via the Affordable Care Act. Oz also had smaller stakes in CVS Health, which now includes the insurer Aetna, and in the insurer Cigna. It’s not clear if Oz, a heart surgeon by training, still holds investments in health care companies, or if he would divest his shares or otherwise seek to mitigate conflicts of interest should he be confirmed by the Senate. Reached by phone on Wednesday, he said he was in a Zoom meeting and declined to comment. An assistant did not reply to an email message with detailed questions. “It’s obvious that over the years he’s cultivated an interest in the pharmaceutical industry and the insurance industry,” said Peter Lurie, president of the Center for Science in the Public Interest, a watchdog group. “That raises a question of whether he can be trusted to act on behalf of the American people.” (The publisher of KFF Health News, David Rousseau, is on the .) Oz used his TikTok page on multiple occasions in November to praise Trump and Robert F. Kennedy Jr., including their efforts to take on the “illness-industrial complex,” and he slammed “so-called experts like the big medical societies” for dishing out what he called bad nutritional advice. Oz’s positions on health policy have been chameleonic; in 2010, he urging Californians to sign up for insurance under President Barack Obama’s Affordable Care Act, telling viewers they had a “historic opportunity.” Oz’s 2022 financial disclosures show that the television star invested a substantial part of his wealth in health care and food firms. Were he confirmed to run CMS, his job would involve interacting with giants of the industry that have contributed to his wealth. Given the breadth of his investments, it would be difficult for Oz to recuse himself from matters affecting his assets, if he still holds them. “He could spend his time in a rocking chair” if that happened, Lurie said. In the past, nominees for government positions with similar potential conflicts of interest have chosen to sell the assets or otherwise divest themselves. For instance, Treasury Secretary Janet Yellen and Attorney General Merrick Garland agreed to divest their holdings in relevant, publicly traded companies when they joined the Biden administration. Trump, however, declined in his first term to relinquish control of his own companies and other assets while in office, and he isn’t expected to do so in his second term. He has not publicly indicated concern about his subordinates’ financial holdings. CMS’ main job is to administer Medicare. About half of new enrollees now choose Medicare Advantage, in which commercial insurers provide their health coverage, instead of the traditional, government-run program, from KFF, a health information nonprofit that includes KFF Health News. Proponents of Medicare Advantage say the private plans offer more compelling services than the government and better manage the costs of care. Critics note that Medicare Advantage plans have a long history of than the traditional program. UnitedHealth, CVS, and Cigna are all substantial players in the Medicare Advantage market. It’s not always a good relationship with the government. The Department of Justice filed a 2017 complaint against UnitedHealth used false information to inflate charges to the government. The case is ongoing. Oz is an enthusiastic proponent of Medicare Advantage. In 2020, he proposed offering Medicare Advantage to all; during his Senate run, he offered a more general pledge to expand those plans. After Trump announced Oz’s nomination for CMS, Jeffrey Singer, a senior fellow at the libertarian-leaning Cato Institute, “uncertain about Dr. Oz’s familiarity with health care financing and economics.” Singer said Oz’s Medicare Advantage proposal could require large new taxes — perhaps a 20% payroll tax — to implement. Oz has gotten a mixed reception from elsewhere in Washington. Pennsylvania Sen. John Fetterman, the Democrat who defeated Oz in 2022, signaled he’d potentially support his appointment to CMS. “If Dr. Oz is about protecting and preserving Medicare and Medicaid, I’m voting for the dude,” on the social platform X. Oz’s investments in companies doing business with the federal government don’t end with big insurers. He and his family also hold hospital stocks, according to his 2022 disclosure, as well as a stake in Amazon worth as much as nearly $2.4 million. (Candidates for federal office are required to disclose a broad range of values for their holdings, not a specific figure.) Amazon operates an internet pharmacy, and the company announced in June that its is available to Medicare enrollees. It also , One Medical, that accepts Medicare and “select” Medicare Advantage plans. Oz was also directly invested in several large pharmaceutical companies and, through investments in venture capital funds, indirectly invested in other biotech and vaccine firms. Big Pharma has been a frequent target of criticism and sometimes conspiracy theories from Trump and his allies. Kennedy, whom Trump has said he’ll nominate to be Health and Human Services secretary, is a longtime anti-vaccine activist. During the Biden administration, Congress gave Medicare authority to negotiate with drug companies over their prices. CMS initially selected 10 drugs. Those drugs collectively accounted for between June 1, 2022, and May 31, 2023, under Medicare’s Part D prescription drug benefit. At least four of those 10 medications are manufactured by companies in which Oz held stock, worth as much as about $50,000. Oz may gain or lose financially from other Trump administration proposals. For example, as of 2022, Oz held investments worth as much as $6 million in fertility treatment providers. To counter fears that politicians who oppose abortion would ban in vitro fertilization, Trump making in vitro fertilization treatment free. It’s unclear whether the government would pay for the services. In his TikTok videos from earlier in November, Oz echoed attacks on the food industry by Kennedy and other figures in his “Make America Healthy Again” movement. They blame processed foods and underregulation of the industry for the poor health of many Americans, concerns shared by many Democrats and more mainstream experts. But in 2022, Oz owned stakes worth as much as $80,000 in Domino’s Pizza, Pepsi, and US Foods, as well as more substantial investments in other parts of the food chain, including cattle; Oz reported investments worth as much as $5.5 million in a farm and livestock, as well as a stake in a dairy-free milk startup. He was also indirectly invested in the restaurant chain Epic Burger. One of his largest investments was in the Pennsylvania-based convenience store chain Wawa, which sells fast food and all manner of ultra-processed snacks. Oz and his wife reported a stake in the company, beloved by many Pennsylvanians, worth as much as $30 million. ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.top 646.ph 。

Fitch has predicted an unfortunate outcome for the naira by 2028, according to its BMI Research report It said the persistent depreciation of the naira will drive up the cost of importing medical devices and diminish consumer purchasing power Despite government incentives, local manufacturing of medical devices in Nigeria still faces significant obstacles Don't miss out! Join Legit.ng's Sports News channel on WhatsApp now! Legit.ng journalist Victor Enengedi has over a decade's experience covering Energy, MSMEs, Technology and the Stock Market. Fitch Solutions, a financial intelligence provider, has forecasted that the naira may fall to around N1,993 per dollar by 2028, posing significant challenges for Nigeria’s pharm*ceutical industry in importing medical devices. In a recent report, BMI Research, a subsidiary of Fitch Solutions, noted that despite the anticipated economic recovery, Nigeria’s medical devices market would likely continue to encounter operational and demand-related difficulties in the short term. Fitch projects that Nigeria’s medical device market will expand at a compound annual growth rate (CAGR) of 10.8% from 2023 to 2028 in local currency terms and 9.6% in US dollar terms, reaching an estimated market value of NGN171.1 billion (USD344.7 million) by 2028. Read also NNPC shares pictures of petrol from pH refinery, says it is ‘top quality’, advises Nigerians PAY ATTENTION : Standing out in social media world? Easy! "Mastering Storytelling for Social Media" workshop by Legit.ng. Join Us Live! The report highlights that increasing healthcare spending focused on universal health coverage, alongside Nigeria's large population and the dual burden of chronic and infectious diseases, will sustain strong demand for medical devices, particularly diagnostics, consumables, and hospital equipment, in the short to medium term. Citing Sanofi and GlaxoSmithKline as examples of companies that exited Nigeria due to naira devaluation, the report noted that the ongoing currency depreciation would drive up the cost of importing medical devices and diminish consumer purchasing power. Fitch’s subsidiary also indicated that, despite government incentives, significant obstacles still prevent local manufacturing of medical devices from gaining momentum in Nigeria. The report stated: “Continued weakness of the naira will increase medical device import costs and erode consumer purchasing power. Similar to other markets in sub-Sahara Africa, Nigeria heavily relies on medical device imports, with reliance of over 95%. We expect that the naira will end 2028 at NGN1993/USD from NGN306/USD in 2018." Read also Rewane advises CBN to stabilise Naira, tame money growth The report highlighted that as the naira depreciates, the cost of importing medical devices will keep rising, which will weaken both the healthcare system and patients' ability to afford essential medical technologies, particularly given the underfunding of the public health sector. However, on the export side, a weaker naira could boost the competitiveness of locally manufactured medical devices, supporting growth in the sector. Tinubu's attempt to manage the naira Years of economic mismanagement have left Nigeria facing a severe shortage of dollars. The country’s economy has long relied on oil exports while maintaining a high demand for imported goods, creating an unstable foundation. In an effort to address this issue, President Bola Tinubu relaxed long-standing foreign exchange controls shortly after assuming office in May 2023. As a result, the naira, previously maintained at an artificially strong rate against the dollar, has depreciated by around 70%. Tinubu aimed to attract foreign investment and enhance Nigeria’s appeal as an investment hub. Read also Report gives new naira prediction for 2024 as currency becomes worse-performing In the short term, however, this shift led to a spike in inflation , reaching a 28-year high, and intensified a cost-of-living crisis that sparked deadly protests in Africa’s most populous nation. Rewane advises CBN to stabilise naira In related news, Legit.ng reported that Bismarck Rewane has proffered solutions to the current state of the Nigerian economy The renowned economist called on the Central Bank of Nigeria (CBN) to focus on stabilising the naira and controlling money supply growth to mitigate inflationary pressures. He also identified forex supply shortages, high energy costs, and poor policy coordination as key factors in economic instability. PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy! Source: Legit.ngNorazibah Md Rabu BINTULU (Dec 14): Petroliam Nasional Berhad (Petronas) has identified 26 clinics in rural areas in Sarawak for medical equipment assistance with funds worth RM1.3 million, said Petronas Sarawak general manager Norazibah Md Rabu. Norazibah said this healthcare initiative reflected Petronas’ ongoing efforts and commitment towards improving clinic facilities in the rural areas. According to her, such an initiative had already benefitted six health clinics in Daro, Sebangan, Tanjung Manis, Machan, Nanga Tau, and Sebauh, Bintulu. “Sebauh Health Clinic has received medical supplies such as a blood pressure monitor, glucometer, portable pulse oximeter, adjustable neck collar, spine board, transcutaneous jaundice detector, fetal doppler, stethoscope, otoscope holder, and others, valued at RM53,000 in total,” she said. Norazibah made these remarks in her speech prior to the presentation of the medical aids – a joint initiative by the Association of Wives of Ministers and Deputy Ministers of Sarawak (Sabati) and Petronas, to a health clinic in Sebauh on Thursday. “As a company that is committed to community, education, and human capital development; Petronas is honoured to be given the opportunity to play a role in improving the living standards of the community. “The Petronas – Sabati collaboration has proven that the spirit of unity, commitment, and concern for the community can produce extraordinary impacts,” she said. Such collaboration with strategic partners, she said, aligned with Petronas’ Positive Social Impact programme that supported equal access to basic healthcare needs and improved the life of the rural communities. Norazibah, who represented the Malaysia LNG Group managing director cum chief executive officer Mohamed Syazwan Abdullah @ Laga Jenggi, was pleased to announce the Group’s additional allocation of RM50,000 as a sign of support towards the cause. “It is hoped that this contribution can be well-utilised to benefit the local community,” she said.Moments ago, the Edmonton Oilers announced that the team has recalled defenceman Josh Brown from the AHL after the injury to Evan Bouchard. In last night's game against the Minnesota Wild , Evan Bouchard took a questionable hit from Ryan Hartman and is labelled as a game time decision for tomorrow night's game. The Oilers signed Josh Brown this offseason to a 3 year contract for $3M , a deal that frankly never made sense, but now he has been recalled for his second stint with the team. Josh Brown is a 30 year old right shot defender that's played 3 games with the Oilers this season. He's a tough physical defender, shown by his 50 penalty minutes in 16 AHL games this year. Edmonton Oilers Recall Defenceman Josh Brown With Evan Bouchard Potentially Injured This season has been a nightmare for Josh Brown and his contract with the Oilers. Brown was cut from the NHL roster in training camp because his preseason play was so bad , despite the 3 year contract commitment. Evan Bouchard was absent from practice today, and Ty Emberson moved up to play the first pair with Mattias Ekholm in his absence. There was a gap on the bottom pair, so if Bouchard is unable to play tomorrow, Josh Brown would potentially be able to slot into that position. The Oilers just claimed defenceman Alec Regula off waivers from the Boston Bruins with the intention of making him the new 7th defenceman, but at the moment, Regula is still not on the active roster due to a knee injury. It seems this roster recall is purely out of precaution if Bouchard is unable to play tomorrow. Hopefully, the Oilers star is healthy enough to play. This article first appeared on Oilers Daily and was syndicated with permission.

James Franklin is under no illusions as to what his alternate reality would have looked like had Penn State dropped Saturday’s road game at Minnesota. That’s because Franklin would be shouldering a lion’s share of the blame. With 3 minutes, 47 seconds to play and Penn State up 26-25, the Nittany Lions faced a fourth-and-1 from their own 34-yard line. The Nittany Lions sent the punt team on the field, with the Gophers about to get a final offensive possession, only for Franklin to call a fake attempt that paid off as Luke Reynolds turned upfield for a 32-yard gain. “If it didn’t work, you wouldn’t be having fun with me talking about the fried turkey or the roasted turkey — you would be roasting James Franklin,” he told reporters in State College Monday. “I totally get that. “Everyone has opinions after the play. For me it just comes down to trusting my staff and, most importantly, trusting the players that it’s about executing what we call.” After the successful fake, Penn State’s offense managed two more first downs, driving deep into Minnesota territory and icing the game. The win improved Penn State, which stayed put at No. 4 in the College Football Playoff rankings, to 10-1 (7-1 Big Ten) on the year. One game remains in the regular season for the Nittany Lions: Maryland (4-7, 1-7) on Saturday afternoon at Beaver Stadium. Franklin’s Nittany Lions remain very much alive for a berth in the Big Ten championship Dec. 7. However, their fate is not totally in their hands. In addition to a win vs. the Terrapins, Penn State needs No. 2 Ohio State (10-1, 7-1) to drop its finale this weekend against Michigan (6-5, 4-4). Top-ranked and undefeated Oregon has punched its ticket to the title game in the Ducks’ inaugural season as Big Ten members. It will be Penn State, Ohio State or No. 10 Indiana (10-1, 7-1) that faces the Ducks. Franklin is aware of the many scenarios that could play out next week, as well as lingering implications regarding CFP seeding. He and his players would welcome a chance to compete for the Big Ten crown, but unsurprisingly, all attention is on the task at hand. “I haven’t spent a whole lot of time thinking about that,” Franklin said. “I’m literally completely focused on the Terps and the University of Maryland, and after that game there (are) a lot of other things I think that have to happen. But that is a possibility. “For us, we want an opportunity to compete as many times as we possibly can this year. If that includes a conference championship game, we would be very, very excited about that opportunity.” Against Maryland and beyond, Penn State will be without two key players on both sides of the ball. Franklin announced Monday that starting right tackle Anthony Donkah and defensive tackle Alonzo Ford suffered unspecified long-term injuries. Looking at the interior defensive line, Penn State’s depth is down to Zane Durant, Devon J-Thomas and Coziah Izzard, all veteran players. Nolan Rucci is expected to step in for Donkah. “I think we were pleased with Rucci, and we sure are glad he’s on our team,” Franklin said. “We felt like that all year long. We’re going to need him to have a really good week this week in preparation, as well as on Saturday, and (we) have a lot of confidence that he will.”AP Business SummaryBrief at 1:06 p.m. ESTSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Zeta Global Holdings Corp. (NYSE: ZETA) securities between February 27, 2024 and November 13, 2024. Zeta is a marketing technology company. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Zeta Global Holdings Corp. (ZETA) Failed to Disclose it was Artificially Inflating Financial Results According to the complaint, on November 13, 2024, market research group Culper Research published a report entitled "Zeta Global Holdings Corp (ZETA): Shams, Scams, and Spam.” The report alleged that the “integrity of the Company’s data collection and reported financials” is severely undermined by two factors. First, the report alleged that “Zeta has formed ‘two-way’ contracts with third party consent farms wherein the Company simultaneously acts as both a supplier and a buyer of consumer data,” allowing the Company to “flatter reported revenue growth” and indicating possible “round-tripping” of revenue. Second, the report alleged that Zeta’s collects the majority of its customer data from a network of “sham websites that hoodwink millions of consumers each month into handing their data over to Zeta under false pretenses.” For example, the report alleged the Company and its subsidiaries operate a number of fake job boards which are designed to trick individuals into submitting personal data under the pretense of job applications. The report further alleged that the Company’s “most valuable data” comes from these predatory websites, dubbed consent farms, which are “responsible for almost the entirety of the Company’s growth.” On this news, the Company’s stock price fell $10.46, or 37.07%, to close at $17.76 per share on November 13, 2024. Plaintiff alleges that during the class period, defendants failed to disclose that: (1) Zeta used two-way contracts to artificially inflate financial results; (2) Zeta engaged in round trip transactions to artificially inflate financial results; (3) Zeta utilized predatory consent farms to collect user data; and (4) that these consent farms have driven almost the entirety of Zeta’s growth. What Now: You may be eligible to participate in the class action against Zeta Global Holdings Corp. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by January 21, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Zeta Global Holdings Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9e62a12-06db-424e-a9a1-12ca4ed447d5

Swiggy announces flash sale on onions after customer’s viral request

Quest Partners LLC raised its stake in Shake Shack Inc. ( NYSE:SHAK – Free Report ) by 76.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 752 shares of the company’s stock after buying an additional 325 shares during the quarter. Quest Partners LLC’s holdings in Shake Shack were worth $78,000 as of its most recent filing with the Securities and Exchange Commission. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SHAK. Russell Investments Group Ltd. boosted its stake in Shake Shack by 61,625.0% during the 1st quarter. Russell Investments Group Ltd. now owns 2,469 shares of the company’s stock worth $257,000 after acquiring an additional 2,465 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Shake Shack by 7.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,883 shares of the company’s stock worth $2,173,000 after purchasing an additional 1,358 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Shake Shack in the 1st quarter valued at $653,000. Quent Capital LLC grew its holdings in shares of Shake Shack by 2,469.1% in the 2nd quarter. Quent Capital LLC now owns 2,081 shares of the company’s stock valued at $187,000 after buying an additional 2,000 shares during the period. Finally, CWM LLC increased its position in shares of Shake Shack by 24.7% in the 2nd quarter. CWM LLC now owns 1,046 shares of the company’s stock valued at $94,000 after buying an additional 207 shares in the last quarter. Institutional investors own 86.07% of the company’s stock. Shake Shack Trading Up 0.9 % Shares of NYSE:SHAK opened at $133.55 on Friday. Shake Shack Inc. has a one year low of $59.94 and a one year high of $134.90. The stock has a market capitalization of $5.67 billion, a PE ratio of 785.59, a price-to-earnings-growth ratio of 3.01 and a beta of 1.81. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.01 and a quick ratio of 1.98. The company’s 50-day moving average price is $115.98 and its two-hundred day moving average price is $102.14. Insider Buying and Selling at Shake Shack In other Shake Shack news, Director Daniel Harris Meyer sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $110.08, for a total value of $1,100,800.00. Following the sale, the director now owns 460,337 shares in the company, valued at $50,673,896.96. This represents a 2.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link . Also, CFO Katherine Irene Fogertey sold 321 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $103.93, for a total value of $33,361.53. Following the completion of the sale, the chief financial officer now directly owns 36,180 shares of the company’s stock, valued at approximately $3,760,187.40. The trade was a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 63,433 shares of company stock worth $7,654,856 over the last quarter. 9.73% of the stock is currently owned by insiders. Wall Street Analysts Forecast Growth SHAK has been the topic of several recent analyst reports. JPMorgan Chase & Co. reiterated an “underweight” rating and set a $102.00 target price (down from $105.00) on shares of Shake Shack in a report on Tuesday, September 24th. TD Cowen reiterated a “buy” rating and set a $125.00 price objective on shares of Shake Shack in a report on Wednesday, September 18th. Oppenheimer increased their target price on Shake Shack from $122.00 to $135.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Bank of America raised their target price on shares of Shake Shack from $104.00 to $116.00 and gave the stock a “neutral” rating in a report on Monday, August 19th. Finally, Piper Sandler cut shares of Shake Shack from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $121.00 to $114.00 in a report on Monday, August 19th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $112.94. View Our Latest Report on Shake Shack Shake Shack Company Profile ( Free Report ) Shake Shack Inc owns, operates, and licenses Shake Shack restaurants (Shacks) in the United States and internationally. Its Shacks offers hamburgers, chicken, hot dogs, crinkle cut fries, shakes, frozen custard, beer, wine, and other products. The company was founded in 2001 and is headquartered in New York, New York. Read More Five stocks we like better than Shake Shack What is the Nasdaq? Complete Overview with History The Latest 13F Filings Are In: See Where Big Money Is Flowing How to Invest in Insurance Companies: A Guide 3 Penny Stocks Ready to Break Out in 2025 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential Want to see what other hedge funds are holding SHAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shake Shack Inc. ( NYSE:SHAK – Free Report ). Receive News & Ratings for Shake Shack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shake Shack and related companies with MarketBeat.com's FREE daily email newsletter .

BJP MLA Jayanarayan Mishra accuses party of sidelining him

Intech Investment Management LLC reduced its stake in Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ) by 47.0% during the 3rd quarter, Holdings Channel reports. The fund owned 6,639 shares of the specialty pharmaceutical company’s stock after selling 5,880 shares during the quarter. Intech Investment Management LLC’s holdings in Jazz Pharmaceuticals were worth $740,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Swedbank AB purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $106,936,000. Rubric Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth approximately $65,812,000. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares during the period. Baupost Group LLC MA raised its holdings in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after acquiring an additional 440,552 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after acquiring an additional 427,246 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors. Insider Activity at Jazz Pharmaceuticals In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. 4.20% of the stock is owned by insiders. Analyst Ratings Changes View Our Latest Analysis on JAZZ Jazz Pharmaceuticals Price Performance JAZZ stock opened at $121.59 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. The business has a 50 day simple moving average of $114.87 and a 200-day simple moving average of $111.12. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. Jazz Pharmaceuticals Profile ( Free Report ) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Recommended Stories Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ). Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .Judge grants dismissal of election subversion case against Trump

Darius Tahir | (TNS) KFF Health News President-elect Donald Trump’s choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace — celebrity doctor Mehmet Oz — recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest. Oz’s holdings, some shared with family, included a stake in UnitedHealth Group worth as much as $600,000, as well as shares of pharmaceutical firms and tech companies with business in the health care sector, such as Amazon. Collectively, Oz’s investments total tens of millions of dollars, according to financial disclosures he filed during his failed 2022 run for a Pennsylvania U.S. Senate seat. Trump said Tuesday he would nominate Oz as administrator of the Centers for Medicare & Medicaid Services. The agency’s scope is huge: CMS oversees coverage for more than 160 million Americans, nearly half the population. Medicare alone accounts for approximately $1 trillion in annual spending, with over 67 million enrollees. UnitedHealth Group is one of the largest health care companies in the nation and arguably the most important business partner of CMS, through which it is the leading provider of commercial health plans available to Medicare beneficiaries. UnitedHealth also offers managed-care plans under Medicaid, the joint state-federal program for low-income people, and sells plans on government-run marketplaces set up via the Affordable Care Act. Oz also had smaller stakes in CVS Health, which now includes the insurer Aetna, and in the insurer Cigna. It’s not clear if Oz, a heart surgeon by training, still holds investments in health care companies, or if he would divest his shares or otherwise seek to mitigate conflicts of interest should he be confirmed by the Senate. Reached by phone on Wednesday, he said he was in a Zoom meeting and declined to comment. An assistant did not reply to an email message with detailed questions. “It’s obvious that over the years he’s cultivated an interest in the pharmaceutical industry and the insurance industry,” said Peter Lurie, president of the Center for Science in the Public Interest, a watchdog group. “That raises a question of whether he can be trusted to act on behalf of the American people.” (The publisher of KFF Health News, David Rousseau, is on the CSPI board .) Oz used his TikTok page on multiple occasions in November to praise Trump and Robert F. Kennedy Jr., including their efforts to take on the “illness-industrial complex,” and he slammed “so-called experts like the big medical societies” for dishing out what he called bad nutritional advice. Oz’s positions on health policy have been chameleonic; in 2010, he cut an ad urging Californians to sign up for insurance under President Barack Obama’s Affordable Care Act, telling viewers they had a “historic opportunity.” Oz’s 2022 financial disclosures show that the television star invested a substantial part of his wealth in health care and food firms. Were he confirmed to run CMS, his job would involve interacting with giants of the industry that have contributed to his wealth. Given the breadth of his investments, it would be difficult for Oz to recuse himself from matters affecting his assets, if he still holds them. “He could spend his time in a rocking chair” if that happened, Lurie said. In the past, nominees for government positions with similar potential conflicts of interest have chosen to sell the assets or otherwise divest themselves. For instance, Treasury Secretary Janet Yellen and Attorney General Merrick Garland agreed to divest their holdings in relevant, publicly traded companies when they joined the Biden administration. Trump, however, declined in his first term to relinquish control of his own companies and other assets while in office, and he isn’t expected to do so in his second term. He has not publicly indicated concern about his subordinates’ financial holdings. CMS’ main job is to administer Medicare. About half of new enrollees now choose Medicare Advantage, in which commercial insurers provide their health coverage, instead of the traditional, government-run program, according to an analysis from KFF, a health information nonprofit that includes KFF Health News. Proponents of Medicare Advantage say the private plans offer more compelling services than the government and better manage the costs of care. Critics note that Medicare Advantage plans have a long history of costing taxpayers more than the traditional program. UnitedHealth, CVS, and Cigna are all substantial players in the Medicare Advantage market. It’s not always a good relationship with the government. The Department of Justice filed a 2017 complaint against UnitedHealth alleging the company used false information to inflate charges to the government. The case is ongoing. Oz is an enthusiastic proponent of Medicare Advantage. In 2020, he proposed offering Medicare Advantage to all; during his Senate run, he offered a more general pledge to expand those plans. After Trump announced Oz’s nomination for CMS, Jeffrey Singer, a senior fellow at the libertarian-leaning Cato Institute, said he was “uncertain about Dr. Oz’s familiarity with health care financing and economics.” Singer said Oz’s Medicare Advantage proposal could require large new taxes — perhaps a 20% payroll tax — to implement. Oz has gotten a mixed reception from elsewhere in Washington. Pennsylvania Sen. John Fetterman, the Democrat who defeated Oz in 2022, signaled he’d potentially support his appointment to CMS. “If Dr. Oz is about protecting and preserving Medicare and Medicaid, I’m voting for the dude,” he said on the social platform X. Oz’s investments in companies doing business with the federal government don’t end with big insurers. He and his family also hold hospital stocks, according to his 2022 disclosure, as well as a stake in Amazon worth as much as nearly $2.4 million. (Candidates for federal office are required to disclose a broad range of values for their holdings, not a specific figure.) Amazon operates an internet pharmacy, and the company announced in June that its subscription service is available to Medicare enrollees. It also owns a primary care service , One Medical, that accepts Medicare and “select” Medicare Advantage plans. Oz was also directly invested in several large pharmaceutical companies and, through investments in venture capital funds, indirectly invested in other biotech and vaccine firms. Big Pharma has been a frequent target of criticism and sometimes conspiracy theories from Trump and his allies. Kennedy, whom Trump has said he’ll nominate to be Health and Human Services secretary, is a longtime anti-vaccine activist. During the Biden administration, Congress gave Medicare authority to negotiate with drug companies over their prices. CMS initially selected 10 drugs. Those drugs collectively accounted for $50.5 billion in spending between June 1, 2022, and May 31, 2023, under Medicare’s Part D prescription drug benefit. At least four of those 10 medications are manufactured by companies in which Oz held stock, worth as much as about $50,000. Related Articles National Politics | Special counsel moves to dismiss election interference, classified documents cases against Trump National Politics | Joe Biden begins final White House holiday season with turkey pardons for ‘Peach’ and ‘Blossom’ National Politics | Donald Trump Jr. emerges as a political force of his own as he helps his father launch a second term National Politics | The rising price of paying the national debt is a risk for Trump’s promises on growth and inflation National Politics | What to know about Brooke Rollins, Trump’s pick for agriculture secretary Oz may gain or lose financially from other Trump administration proposals. For example, as of 2022, Oz held investments worth as much as $6 million in fertility treatment providers. To counter fears that politicians who oppose abortion would ban in vitro fertilization, Trump floated during his campaign making in vitro fertilization treatment free. It’s unclear whether the government would pay for the services. In his TikTok videos from earlier in November, Oz echoed attacks on the food industry by Kennedy and other figures in his “Make America Healthy Again” movement. They blame processed foods and underregulation of the industry for the poor health of many Americans, concerns shared by many Democrats and more mainstream experts. But in 2022, Oz owned stakes worth as much as $80,000 in Domino’s Pizza, Pepsi, and US Foods, as well as more substantial investments in other parts of the food chain, including cattle; Oz reported investments worth as much as $5.5 million in a farm and livestock, as well as a stake in a dairy-free milk startup. He was also indirectly invested in the restaurant chain Epic Burger. One of his largest investments was in the Pennsylvania-based convenience store chain Wawa, which sells fast food and all manner of ultra-processed snacks. Oz and his wife reported a stake in the company, beloved by many Pennsylvanians, worth as much as $30 million. ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.TV’s Dr. Oz invested in businesses regulated by agency Trump wants him to lead

Intel’s interim co-CEO Michelle Johnston Holthaus spoke at Barclay’s Global Technology Conference yesterday and made some bold claims about Qualcomm PCs and the rise of the Arm ecosystem in general. According to her, a large percentage of Qualcomm PCs are being returned by customers and retailers are very concerned about it. More specifically, she called the problem any retailer’s “number one concern.” There isn’t a lot of available data out there about Qualcomm’s return rates this year, so it’s difficult to fact-check this. The assumption is that the reason for return would have to do with compatibility issues with Windows on Arm , though that’s far less of a concern today than it was in the past. According to Canalys , Qualcomm sold 720,000 PCs during the third quarter, giving it a market share of around 0.8%. That marks huge growth for the company, but there’s no denying that the number is still very small. Practically speaking, it seems unlikely that any retailer would be majorly concerned about the return rate of a product with such relatively low sales. Accuracy aside, it seems like Johnston Holthaus wants this anecdote to illustrate that, while Qualcomm and Arm PCs in general are becoming a serious competitor for Intel , they are currently far from posing an existential threat. She says Intel believes that “x86 is the best overall basic architecture” and that they have many customers who are willing to put their trust in x86 and Intel’s future. Her apparent desire to put the Arm movement in its place could be seen as a reaction to recent comments from TSMC founder Morris Chang a few days ago. When asked about the recent change in Intel leadership , Chang mentioned that Intel has no strategy and no CEO and that it has probably made a big mistake by not focusing on AI processors. Given TSMC’s partnerships with companies like Nvidia, Apple, and Qualcomm, Johnston Holthaus may have wanted to remind them all that, despite everything, Intel is still the one on top. Aside from the harsh comments on Qualcomm, the co-CEO talked about how “competition makes us better” and pushes constant innovation and improvement. She also alluded to even more competitors coming in the future by saying: “We [will] have more competitors than we have ever had, you will see more competitors enter the marketplace in 2025.”NoneTwo properties were "significantly damaged" after suspicious devices were thrown at them in the early hours of this morning. Shortly after 2am this morning, November 30, police received reports of "two loud explosions" in the Carnary Drive area of Ballymoney , with a security alert announced. Police discovered the remnants of two suspicious devices which had been thrown at properties in the area, causing significant damage. Read more: Firefighters remove occupants from flat following arson attack The security alert has now ended and police are continuing their investigation with an appeal for anyone with information to get in touch. Detective Inspector Hanbidge said: “Shortly after 2am this morning, Saturday 30th November, we received reports of two loud explosions in the area. “Officers attended and discovered the remnants of two suspicious devices which had been thrown at two properties and exploded causing significant damage. “This security alert was in a busy residential area and could have caused serious injury or even worse. We would like to thank residents for their understanding and patience as we conducted our investigations. “Our enquiries are continuing and anyone with any information is asked to contact us on 101, quoting reference number 139 of 30/11/24.” A report can also be submitted online using the non-emergency reporting form via http://www.psni.police.uk/makeareport/ or contact Crimestoppers anonymously on 0800 555 111 or online at http://crimestoppers-uk.org/ Join our Belfast Live breaking news service on WhatsApp Click this link or scan the QR code to receive breaking news and top stories from Belfast Live. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don’t like our community, you can check out any time you like. If you’re curious, you can read our Privacy Notice . For all the latest news, visit the Belfast Live homepage here and sign up to our politics newsletter here.

Article content A federation of student associations at Université de Montréal is the latest organization to ink a deal with social economy enterprise UTILE to build off-campus non-profit student housing in Montreal. The Fédération des associations étudiantes du campus de l’Université de Montréal (FAÉCUM) and UTILE announced on Thursday they have signed an agreement to build a project comprising affordable apartments for at least 150 students. “By investing in student housing, FAÉCUM is taking a step toward a future where access to housing will no longer be an obstacle to academic success,” federation secretary general Méganne Joyal said in a statement. “FAÉCUM hopes that today’s announcement will inspire other stakeholders to take action to ensure equitable access to housing for the entire student community.” The federation, which represents 85 student associations and about 40,000 students at Université de Montréal, has committed to investing up to $2 million toward the project, with the exact amount dependent on how many units are built for the Université de Montréal student population. UTILE, which stands for Unité de travail pour l’implantation de logement étudiant, has so far completed 600 units of affordable student rental housing in Quebec. Its first project was the 90-unit Woodnote on Papineau Ave., which got off the ground with $1.85 million in seed money from the Concordia Student Union. New projects include a $63-million, 13-storey building that started construction in downtown Montreal in October. The latter, called Le Méridien, was launched with $1.5 million in seed money from the Students’ Society of McGill University. UTILE was launched more than a decade ago by a group of Université du Québec à Montréal students who wanted to develop an alternative for students to the traditional dorm room and high-rent and overcrowded apartments. UTILE president, CEO and co-founder Laurent Levesque said Thursday that the company is scouting property in the area around Université de Montréal’s MIL campus in Outremont to develop the new project. FAÉCUM’s investment will be injected into the Popular University Student Housing (PUSH) Fund, a non-profit rotating investment fund known as Fonds CLÉ in French that has provided the startup funds for other UTILE projects. UTILE leverages the seed money from student associations to seek other financing. “It is a great source of pride for us to launch a very first project north of the mountain for the student population of the Université de Montréal,” Levesque said in the statement about the partnership with FAÉCUM. The federation’s investment, he added, “will provide a living environment adapted to the needs of at least 150 students and will allow them to fully realize their potential.” lgyulai@postmedia.comSVG Summit Technology Exhibits Preview, Part 2

THE HAGUE (AP) — The world’s top war-crimes court issued arrest warrants Thursday for Israeli Prime Minister Benjamin Netanyahu, his former defense minister and Hamas’ military chief, accusing them of crimes against humanity in connection with the 13-month war in Gaza. The warrants said there was reason to believe Netanyahu and former Defense Minister Yoav Gallant have used “starvation as a method of warfare” by restricting humanitarian aid and have intentionally targeted civilians in Israel’s campaign against Hamas in Gaza — charges Israeli officials deny. The action by the International Criminal Court came as the death toll from Israel’s campaign in Gaza passed 44,000 people, according to local health authorities, who say more than half of those killed were women and children. Their count does not differentiate between civilians and combatants. Experts say hunger has become widespread across Gaza and may have reached famine levels in the north of the territory, which is under siege by Israeli troops. Israel says it has been working hard to improve entry of aid, though the trickle of supplies into Gaza remains near the lowest levels of the war. Netanyahu condemned the warrant against him, saying Israel “rejects with disgust the absurd and false actions” by the court. In a statement released by his office, he said: “There is nothing more just than the war that Israel has been waging in Gaza.” Gallant, in a statement, said the decision "sets a dangerous precedent against the right to self-defense and moral warfare and encourages murderous terrorism.” The warrant marked the first time that a sitting leader of a major Western ally has been accused of war crimes and crimes against humanity by a global court of justice. TH(backslash)he decision turns Netanyahu and the others into internationally wanted suspects, putting them at risk of arrest when they travel abroad and potentially further isolating them . Israel and its top ally, the United States, are not members of the court. But others of Israel's allies, including some of its close European friends, are put in an awkward position. Several, including France, welcomed the court's decision and signaled they might arrest Netanyahu if he visited. The move “represents the most dramatic step yet in the court’s involvement in the conflict between Israel and Hamas," said Anthony Dworkin, senior policy fellow at the European Council on Foreign Relations. Israeli leaders, politicians and officials across the spectrum denounced the warrants and the ICC. The new defense minister, Israel Katz, who replaced Gallant earlier this month, said Thursday’s decision is “a moral disgrace, entirely tainted by antisemitism, and drags the international judicial system to an unprecedented low.” Human rights groups applauded the move. The warrants against both sides “break through the perception that certain individuals are beyond the reach of the law,” the associate international justice director at Human Rights Watch, Balkees Jarrah, said in a statement. The decision came six months after ICC Chief Prosecutor Karim Khan requested the warrants. The court issued a warrant for Mohammed Deif, head of Hamas’ armed wing, over the Oct. 7, 2023, attacks that triggered Israel’s offensive in Gaza. It said it found reasonable grounds to believe Deif was involved in murder, rape, torture and the taking of hostages amounting to war crimes and crimes against humanity. In the Hamas-led attack, militants stormed into southern Israel, killing 1,200 people — mostly civilians — and taking some 250 others hostage. Around 100 Israelis remain captive in Gaza, around a third of them believed to be dead. Khan withdrew requests for warrants for two other senior Hamas figures, Yahya Sinwar and Ismail Haniyeh , who have both since been killed. Israel says it also killed Deif in an airstrike, but Hamas has never confirmed his death. The warrants for Netanyahu and Gallant were issued by a three-judge panel in a unanimous decision. The panel said there were reasonable grounds to believe that both men bear responsibility for the war crime of starvation and the crimes against humanity of murder, persecution and other inhumane acts. The judges said the lack of food, water, electricity, fuel and specific medical supplies created conditions “calculated to bring about the destruction of part of the civilian population in Gaza,” including the deaths of children due to malnutrition and dehydration. They also found that by preventing hospital supplies and medicine from getting into Gaza, doctors were forced to operate, including performing amputations, without anesthesia or with unsafe means of sedation that led to “great suffering.” Israeli diplomatic officials said the government is lobbying the international community to speak out against the warrants and is considering an appeal to the court. The officials spoke on condition of anonymity pending a formal decision on how the government will proceed. Despite the warrants, none of the suspects is likely to face judges in The Hague anytime soon. Member countries are required to detain suspects facing a warrant if they set foot on their soil, but the court has no way to enforce that. For example, Russian President Vladimir Putin, wanted on an ICC warrant for alleged war crimes in Ukraine, recently visited Mongolia, a member state in the court but also a Russian ally. He was not arrested. Still, the threat of arrest now complicates any travel abroad by Netanyahu and Gallant. EU foreign policy chief Josep Borrell said the warrants are binding on all 27 members countries of the European Union. France signaled it could arrest Netanyahu if he came to its territory. Foreign Ministry spokesman Christophe Lemoine called it a “complex legal issue” but said France supports the court’s actions. “Combating impunity is our priority,” he said. “Our response will align with these principles.” Hamas in a statement welcomed the warrants against Netanyahu and Gallant but made no mention of the one against Deif. Israel’s opposition leaders fiercely criticized the ICC’s move. Benny Gantz, a retired general and political rival to Netanyahu, said it showed “moral blindness” and was a “shameful stain of historic proportion that will never be forgotten.” Israel’s campaign has caused heavy destruction across Gaza and driven almost the entire population of 2.3 million people from their homes, leaving most dependent on aid to survive. Two days after Hamas’ attack on southern Israel, Gallant announced a total seal on Gaza, vowing not to let in food, fuel or other supplies. Under U.S. pressure, Israel began allowing a trickle of humanitarian aid to enter a few weeks later. Israel now says it puts no limit on the supplies permitted into Gaza, and it blames the U.N. distribution system. But Israel's official figures show the amount of aid it has let in has plunged since the beginning of October. The U.N has blamed Israeli military restrictions, along with widespread lawlessness that has led to theft of aid shipments. The case at the ICC is separate from another legal battle Israel is waging at the top U.N. court, the International Court of Justice, in which South Africa accuses Israel of genocide , an allegation Israeli leaders staunchly deny. Lawyers for Israel argued in court that the war in Gaza was a legitimate defense of its people and that it was Hamas militants who were guilty of genocide. Associated Press journalists Raf Casert in Brussels, Mike Corder in The Hague and Josef Federman in Jerusalem contributed to this report.US Steel shares drop after Biden plans to block Nippon Steel deal - Bloomberg